Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?
Giulia MarvasoMarianna MontesanoGiulia CorraoSimone P De AngelisSara GandiniGiovanni C MazzolaMatteo AugugliaroJessica FranzettiDario ZeriniMatteo PepaStefano LuzzagoFrancesco A MistrettaGennaro MusiFranco NolèOttavio De CobelliRoberto OrecchiaBarbara Alicja Jereczek-FossaPublished in: BJU international (2020)
Our data confirmed the encouraging outcomes of patients with pN1 PCa treated with adjuvant treatments and the key role represented by the number of pN1s in predicting biochemical RFS, clinical RFS and distant RFS. Large prospective cohort studies and randomized clinical trials are needed to confirm these results and to identify the subgroup of patients with pN1 PCa who would most benefit from aRT.
Keyphrases
- prostate cancer
- early stage
- end stage renal disease
- newly diagnosed
- lymph node
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- radiation therapy
- prognostic factors
- radical prostatectomy
- randomized controlled trial
- hiv infected
- electronic health record
- clinical trial
- big data
- squamous cell carcinoma
- adipose tissue
- machine learning
- deep learning